Calcitriol Inhibits Viability and Proliferation in Human Malignant Pleural Mesothelioma Cells by Gesmundo, I. et al.
ORIGINAL RESEARCH
published: 08 October 2020
doi: 10.3389/fendo.2020.559586
Frontiers in Endocrinology | www.frontiersin.org 1 October 2020 | Volume 11 | Article 559586
Edited by:
Wen Zhou,




University of Eastern Piedmont, Italy
Clara Crescioli,




†These authors have contributed
equally to this work
‡Deceased
In Memoriam:
This paper is dedicated to the
memory of Giacomo Gamba who
passed away on May 23rd 2020
Specialty section:
This article was submitted to
Cancer Endocrinology,
a section of the journal
Frontiers in Endocrinology
Received: 06 May 2020
Accepted: 28 August 2020
Published: 08 October 2020
Citation:
Gesmundo I, Silvagno F, Banfi D,
Monica V, Fanciulli A, Gamba G,
Congiusta N, Libener R, Riganti C,
Ghigo E and Granata R (2020)
Calcitriol Inhibits Viability and




Calcitriol Inhibits Viability and
Proliferation in Human Malignant
Pleural Mesothelioma Cells
Iacopo Gesmundo 1†, Francesca Silvagno 2†, Dana Banfi 1, Valentina Monica 2,3,
Alessandro Fanciulli 1, Giacomo Gamba 1‡, Noemi Congiusta 1, Roberta Libener 4,
Chiara Riganti 2, Ezio Ghigo 1 and Riccarda Granata 1*
1Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy,
2Department of Oncology, University of Turin, Turin, Italy, 3Candiolo Cancer Institute-Fondazione del Piemonte per
l’Oncologia (FPO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy, 4 Pathology Unit, SS. Antonio e
Biagio General Hospital, Alessandria, Italy
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, often associated
with exposure to asbestos and characterized by poor prognosis and limited treatment
options. The biologically active form of vitamin D, calcitriol, exerts anticancer effects
in many cell types, both alone and in combination with chemotherapy drugs, through
binding to vitamin D receptor (VDR); however, the role of calcitriol in MPM is still unknown.
This study aimed to determine the potential antitumor role of calcitriol in MPM. The results
showed that calcitriol reduces cell viability and proliferation in human MPM cells lines,
which express both cytoplasmic and nuclear VDR; furthermore, calcitriol potentiated
the inhibitory activity of the chemotherapy drug PEM. These effects were paralleled
by cell cycle arrest and inhibition in expression of c-Myc and cyclins involved in cell
cycle progression. Exposure of MPM cells to calcitriol also produced an alteration in
mitochondrial function and inhibition in the expression of respiratory chain complex
subunits. Finally, the inhibitory effects of calcitriol were also observed on viability of human
primary MPM cells. Collectively, these results indicate a novel anticancer role for calcitriol
in MPM, suggesting potential for vitamin D derivatives, alone or in combination with
chemotherapy, in the treatment of this malignancy.
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INTRODUCTION
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor with a dismal prognosis,
that occurs because of malignant transformation of pleural mesothelial cells. The principal cause
of MPM development is exposure to asbestos, although different minerals, such as erionite and
radiation therapy in patients treated for other cancers, have been also implicated (1). Exposure to
asbestos generates a chronic inflammatory state, with activation of macrophages, production of
reactive oxygen species and mediators of inflammation, such as cyclooxygenases, cytokines and
growth factors, all promoting tumor formation (2). Pathologically, some MPM have an epithelial
morphology, the most frequent and less malignant variant, others sarcomatoid, with the worst
prognosis, while a mixed biphasic population comprising both histologic subtypes also exists (2, 3).
The first-line treatment for inoperable patients with MPM consists in a combination of cisplatin
and the antifolate pemetrexed (PEM), which, however, increase overall survival only of 9–12
months, therefore, novel therapeutic strategies are urgently needed (4).
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The active form of vitamin D, the steroid hormone 1α,25-
dihydroxyvitamin D3 or calcitriol, regulates many biological
processes, mostly mediated by the nuclear vitamin D receptor
(VDR), which acts through both genomic, and non-genomic
mechanisms (5). Calcitriol has an essential role in calcium
homeostasis and also modulates biological functions, including
cell growth, wound healing, neuromuscular, and immune
functions. In addition, calcitriol shows potential anticancer
activity by regulating signaling pathways involved in cell
proliferation, differentiation, apoptosis, inflammation, invasion,
angiogenesis, and metastasis (6, 7). Indeed, studies have
demonstrated the antiproliferative and pro-differentiating effects
of calcitriol in vitro, in several cancer cell models. Moreover,
calcitriol and its analogs, alone or in combination with anticancer
drugs, showed the ability to delay initiation and inhibit tumor
progression in vivo, in animal models of cancer (5–7). Clinical
trials have been also undertaken in different cancers; however,
the responses were modest, likely because the doses of the
compounds were too conservative, the studies inappropriately
designed and conducted in patients with far-advanced disease
(5, 7–9).
The resistance to the antiproliferative effects of the hormone
is due to many causes, some linked to a defective expression
or function of VDR or aberrant expression of vitamin D-
metabolizing enzymes, others because of epigenetic mechanisms
that may disrupt VDR signaling (6). Indeed, the presence of VDR
in cancer cells is essential for the activity of calcitriol and high
VDR expression has been associated with improved prognosis
and reduced risk of death from cancer (5, 6).
VDR is present mainly in metabolic tissues, but also in almost
all human cell types (10); furthermore, VDR expression is low
in normal cells, increases in malignant cells and is reduced
with tumor growth (5, 11). VDR is also expressed in human
and rodent peritoneal mesothelial cells and human bronchial
epithelial cells (12–15); however, the presence of VDR in pleural
mesothelial cells has yet to be demonstrated. Studies have recently
indicated that calcitriol reduces fibrosis and prevents epithelial-
mesenchymal transition in human peritoneal mesothelial cells in
vitro (12, 14), while vitamin D analogs reduce peritoneal fibrosis
in vivo (15) through antinflammatory mechanisms. In addition
to its nuclear localization, VDR has been recently localized in
mitochondria and calcitriol was found to suppress mitochondrial
respiration in cancer cell lines, keratinocytes and adipocytes,
affecting both cell growth and differentiation, as well as lipid
metabolism (16–19).
Only one study examined the role of vitamin D in
mesothelioma to date (20). The Authors reported that dietary
supplementation with cholecalciferol (vitamin D3) in transgenic
mice exposed to asbestos did not reduce the incidence or
severity of peritoneal mesothelioma. However, differently from
most studies performed in human cancer xenografts (5, 8, 21),
the effects of cholecalciferol were assessed in a mouse model
of asbestos-induced mesothelioma and the direct action of
cholecalciferol in mesothelioma cells was not examined.
Based on the abovementioned data and because of its
antiproliferative, antinflammatory and antioxidant activities, we
hypothesized that vitamin D would exert direct inhibitory effects
in MPM cells. Thus, in the present study we examined the role
of calcitriol, alone or in combination with chemotherapeutic
drugs, on viability and proliferation of humanMPM cell lines and
primary cells obtained from patients withMPM; furthermore, we
analyzed the mechanisms involved in these effects.
METHODS
Reagents
1,25(OH)2D3 (Calcitriol), Pemetrexed, 2,5-diphenyl tetrazolium
bromide (MTT), Roswell Park Memorial Institute (RPMI)-1640
medium, Ham’s F12 medium, fetal bovine serum (FBS), bovine
serum albumin (BSA), penicillin, streptomycin, amphotericin B,
L-glutamine, primers and cell culture reagents were from Sigma-
Aldrich (Milan, Italy). RT-PCR and Real-Time PCR reagents
were from Life Technologies, Inc. (Invitrogen, Milan, Italy).
Cell Lines
The human biphasic MPM cell line MSTO-211H and the human
mesothelial cell line MeT-5A were purchased from American
Type Culture Collection (ATCC; Manassas, VA, USA). The
human epithelioid MPM cell line REN was kindly provided by
Prof. Giorgio Scagliotti (Department of Oncology, University of
Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy), as
described previously (22). Cells were maintained at 37◦C in a 5%
CO2 humidified atmosphere in RPMI-1640 with 10% FBS, 2mM
L-glutamine, penicillin (100 U/ml), streptomycin (100µg/ml)
and 250 ng/mL amphotericin B and used between passages 12
and 25.
Isolation and Culture of Human Primary
MPM Cells
Human Primary MPM cells (3 epithelioid MPM, 3 biphasic
MPM, 3 sarcomatoid MPM) were isolated from diagnostic
thoracoscopies of MPM patients, as previously described (22).
Briefly, tissues were digested in medium containing 1 mg/ml
collagenase and 0.2 mg/ml hyaluronidase for 1 h at 37◦C. Cells
were seeded in culture and used within passage 6. The study
was approved by the Ethical Committees of the Biological Bank
of Mesothelioma, SS. Antonio and Biagio General Hospital,
Alessandria, Italy, and San Luigi Gonzaga Hospital, Orbassano,
Turin, Italy (#9/11/2011; #126/2016). The patients provided their
written informed consent to participate in this study. Primary
MPM cells were grown in Ham’s F12 medium with 10% of FBS
(normal medium, NM). All culture mediums were supplemented
with L-glutamine (2mM), penicillin (100 U/ml), streptomycin
(100µg/ml), and 250 ng/mL amphotericin B. The cells were
cultured at 37◦C in a 5% CO2 humidified atmosphere.
Cell Viability and Proliferation
Cells were seeded in 96-wells plates at the concentration of 2
× 103 cells/well. After 48 h, cells were serum-starved for 12 h
and incubated with the different stimuli for further 24 h or 72 h.
Cell viability was assessed by 3-[4,5-dimethylthiazole-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay. Briefly, cells were
incubated with 1 mg/ml of MTT for ∼2 h, then the medium
was removed, and formazan products solubilized with 100 µl
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dimethyl sulfoxide (DMSO). Cell proliferation was assessed using
the 5-bromo-2-deoxyuridine (BrdU) incorporation enzyme-
linked immunosorbent assay (ELISA) (Roche Diagnostic)
as previously described (22). Absorbance was assessed by
spectrophotometry at 570 nm for MTT and at 450 nm for BrdU,
using LT-4000 microplate reader (Euroclone, Milan, Italy).
Clonogenic Assay
Colony-forming capacity was analyzed by the clonogenic assay,
as described previously (22). MSTO-211H REN and MeT-
5A cells were seeded into 60mm tissue culture plates, at a
concentration of 1 × 103 cells, and maintained in RPMI-1640
with 10% FBS for 10 days, in either presence or absence of 100 nM
calcitriol. The cells were then fixed with methanol, colonies were
stained with crystal violet (0.05%) and plates photographed using
a digital camera (ChemiDoc XRS). Colonies were counted with
ImageJ software (http://rsbweb.nih.gov/ij/).
Western Blot Analysis
Protein extraction and Western blot analysis were performed as
described previously (23). Total proteins were extracted using
RIPA buffer (Sigma-Aldrich, Milan, Italy). Cytoplasmic and
nuclear proteins were extracted using the Cytoplasmic and
Nuclear Protein Extraction Kit (Immunological Sciences, Rome,
Italy), following themanufacturer’s instructions. Proteins (60µg)
were separated by 10 % sodium dodecyl sulfate—polyacrylamide
gel electrophoresis, (SDS-PAGE), transferred to a nitrocellulose
membrane and incubated overnight at 4◦C with the specific
Vitamin D3 Receptor antibody (dilution 1:1000, Cell Signaling,
Beverly, MA, USA). Blots were reprobed with actin or PARP-1
(dilution 1:500, Santa Cruz Biotechnology, Dallas, USA) for
protein normalization. Immunoreactive proteins were visualized
using horseradish peroxidase-conjugated goat anti-mouse or
goat anti-rabbit (1:4000) secondary antibodies (Southernbiotech,
Birmingham, AL, USA) by enhanced chemiluminescence
substrate (ECL) using ChemiDoc XRS (Bio-Rad, Milan, Italy);
densitometric analysis was performed with Quantity One
software (Bio-Rad, Milan, Italy).
Real-Time PCR
Total RNA isolation and reverse transcription to cDNA (1
µg RNA) from MeT-5A, MSTO-211H and REN cells, treated
with TRIzol reagent (Life Technologies, Milan, Italy), were
performed as described previously (22). For real-time PCR,
cDNAs were treated with DNA-free DNase (Life Technologies,
Milan, Italy) and reaction performed with 50 ng cDNA, 100 nM
of each primer and IQ-SYBR-green Mastermix (Bio-Rad) using
the ABI-Prism 7,300 (Applied Biosystems, Milan Italy). The
following primer pairs (designed with the Primer 3 Software,
http://www.primer3.org/) were used: c-Myc, forward 5′- AGCG
ACTCTGAGGAGGAACA-3′, reverse 5′-CTCTGACCTTTT
GCCAGGAG-3′ (NM_002467.5); cyclin-A, forward 5′-AATT
GTGCCTTGCCTGAGTGA-3′, reverse 5′-AAGAACTGCAGG
TGGCTCCAT-3′ (XM_011535295.2); cyclin D1, forward 5′-
ATGTGTGCAGAAGGAGGTCC-3′, reverse 5′- CCTTCATC
TTAGAGGCCACG-3′ (NM_053056.3); cyclin D2, forward
5′-TGCAGAAGGACATCCAACC-3′, reverse 5′-AGGAACAT
GCAGACAGCACC-3′(NM_001759.4); COX2, forward 5′-
CGACTACGGCGGACTAATCT-3′, rev 5′-TCGATTGTCAAC
GTCAAGGA-3′ (EU835118.1); COX4, forward 5′-CGAGCAAT
TTCCACCTCTGT-3′, reverse 5′-GGTCAGCCGATCCATA
TAA-3′(NM_001861.6); 18S rRNA, forward 5′-CCCATTCG
AACGTCTGCCCTATC-3′, reverse 5′-TGCTGCCTTCCT
TGGATGTGGTA- 3′ (NR_146144.1), 18S rRNA was used as
endogenous control. Relative quantification was performed
using the comparative Ct (2−11Ct) method.
Cell Cycle Analysis
Cell cycle analysis was performed as described previously (24),
using the Muse Cell Cycle Kit (Merck-Millipore, Burlington,
MA, USA) according to the manufacturer’s instructions.
Briefly, 5 × 104 cells were seeded in 60-mm dishes and
after 48 h incubated with different concentrations of calcitriol
in medium supplemented with 2.5% FBS for 24 h. Cells
were then detached with phosphate buffered saline (PBS)
1X/ethylenediaminetetraacetic acid (EDTA) (5mM), centrifuged
(1,500 rpm, 5min) and fixed with pre-cooled ethanol. The cells
were then treated with Muse Cell Cycle Reagent for 30min and
analyzed with Muse Cell Analyzer Software (Merck-Millipore,
Burlington, MA, USA).
Measurement of Mitochondrial Membrane
Potential (1Ψm)
1Ψm was assessed by cytofluorimetric analysis using
the fluorescent probe JC-1 (5,5,6,6-tetrachloro-1,1,3,3-
tetraethylbenzimidazole carbocyanide iodide JC-1 (Thermo
Fisher Scientific, Waltham, MA USA), a cationic dye that
shows mitochondrial polarization by shifting its fluorescence
emission from green (530 nm) to red (590 nm). Consequently,
the enhanced mitochondrial activity is indicated by an increase
in the red/green fluorescence intensity ratio (FL2/FL1 channels
of flow cytometer). The cells were treated with calcitriol for
24 h then harvested by trypsinization, washed in PBS (pH
7.4) and incubated with JC-1 (2µg/ml) for 30min at 37◦C.
The amount of JC-1 retained by 1 × 104 cells per sample was
measured at 530 nm (FL-1 green fluorescence) and 590 nm
(FL-2 red fluorescence) using a flow cytometer FACSCalibur
(BD biosciences, Franklin Lakes, NJ, USA) and analyzed with
BD FACStation software (22, 25). 1Ψm was determined as
FL2/FL1 ratio.
Combination Studies
The synergistic effect of the drugs was performed according to the
Chou-Talalay method of synergy quantitation using CompuSyn
software (26). CI values were generated by performing cell
viability assay (MTT) and computerized software data. CI = 1
indicates an additive effect between two drugs; a CI > 1 indicates
antagonism, and a CI < 1 indicates a synergistic effect.
Statistical Analysis
Results are presented asmean± SEM. Significance was calculated
by unpaired two-tailed Student’s t-test or one-way ANOVA
followed by followed by Dunnett’s or Tukey’s post-hoc test, as
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appropriate, using GraphPad Prism v.5 (GraphPad Software,
SanDiego, CA, USA).
RESULTS
Expression of Cytoplasmic and Nuclear
VDR in MPM Cell Lines
To understand the role of calcitriol in MPM cell lines, we first
assessed the presence of VDR. Western blot analysis revealed
VDR protein expression in pleural biphasic MSTO-211H and
epithelioid REN MPM cell lines, as well as in MeT-5A pleural
mesothelial cells. The levels of VDR were significantly higher in
MPM cells, particularly in REN cells, compared with mesothelial
cells, where the receptor was barely detectable (Figure 1A). In
addition, both cytoplasmic and nuclear VDR were increased
in MSTO-211H (Figures 1B,C) and REN cells (Figures 1D,E)
treated for 24 h with 50 and 100 nM calcitriol, compared with
cells untreated. Conversely, no variation was observed in MeT-
5Amesothelial cells, either in the absence or presence of calcitriol
(Figures 1F,G). These results suggest that VDR expression is
higher inMPM cell lines and is further induced by treatment with
its ligand.
Calcitriol Inhibits Viability and Proliferation
in MPM Cell Lines
We next assessed the potential inhibitory effects of calcitriol
in MPM cells. As previously reported, (22), cell viability and
proliferation were reduced of ∼25% in MSTO-211H cells, ∼20–
25% in REN cells and ∼15–18% in Met-5A cells (data not
shown). Treatment with increasing concentrations of calcitriol
(1 to 100 nM) for 24 further produced a dose-dependent
reduction in viability and proliferation of both MSTO-211H
(Figures 2A,B) and REN cells cultured in serum deprived
medium (Figures 2C,D), compared with control. The maximum
effect was observed at 50 nM (MSTO-211H: 22.6 and 17.8%;
REN: 19.5 and 18% for viability and proliferation, respectively);
and 100 nM (MSTO-211H: 24.7 and 31.1%; REN: 24 and
21.3% for viability and proliferation, respectively). By contrast,
viability and proliferation were unchanged in non-malignant
MeT-5A mesothelial cells treated with calcitriol, at any of
the concentrations tested (Figures 2E,F). Similar findings were
obtained for cell viability when the cells were cultured for 24
and 72 h in the presence of 2.5% serum, although the inhibitory
effect of calcitriol was attenuated (100 nM calcitriol at 24 h,
MSTO-211H: 12.8%; REN: 14.9%. 100 nM calcitriol at 72 h,
MSTO-211H: 21.1%; REN: 23.1%) (Supplementary Figure 1).
These findings suggest that calcitriol maintains its inhibitory
activities even for longer-terms and in more physiological
conditions. Because of the best inhibitory effect observed for
both cell viability and proliferation, 100 nM was chosen as
concentration for subsequent studies; in addition, due to the
possible interference caused by serum, the experiments were
performed under serum deprived medium. To further unveil
the ability of calcitriol to reduce cell viability, we conducted
the clonogenic assay and observed that after 10 days treatment,
calcitriol blunted the ability of both MSTO-211H and REN cells
FIGURE 1 | Expression of VDR in MPM cell lines and mesothelial cells. (A)
Total VDR protein assessed by Western blot in MSTO-211H, REN and MeT-5A
cells. Results, normalized to actin and expressed as percent of control are
means ± SEM. ***P < 0.001 vs. MeT-5A; n = 3. Cytosolic and nuclear VDR in
MSTO-211H (B,C), REN (D,E) and MeT-5A cells (F,G), that were serum
deprived for 12 h and either untreated (c, control) or treated for 24 h with
calcitriol (Cal), at the concentrations indicated. Blots are representative of three
independent experiments. Results, normalized to actin and PARP for
cytoplasmic or nuclear VDR, respectively, are expressed as percent of control
and are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. c.; n = 3.
to form colonies, while having no effect in MeT-5A mesothelial
cells (Figures 2G–I).
Calcitriol Potentiates the Inhibitory Effect
of PEM in MPM Cell Lines
Having established its inhibitory function, we subsequently
assessed whether calcitriol increases the cytotoxic effect of
the anticancer drug PEM in MPM cells. MSTO-211H and
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FIGURE 2 | Effect of calcitriol on viability and proliferation of MPM cells and pleural mesothelial cells. MSTO-211H and REN MPM cells, and MeT-5A mesothelial cells,
were serum deprived for 12 h, then cultured for 24 h in the absence (c, control) or presence of calcitriol (Cal), at the concentrations indicated. Cell viability (A,C,E) and
proliferation (B,D,F) were assessed by MTT and BrdU, respectively. Maximum inhibition at 100 nM Cal in MSTO-211H (A,B): 24.7 and 31.1%; REN: 24 and 21.3%,
for viability and proliferation, respectively. Results, expressed as percent of control are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. c; n = 8 for MTT, n = 4
for BrdU. Representative colony formation in MSTO-211H (G), REN (H), and MeT-5A cells (I) untreated (c, control) or treated for 10 d with calcitriol (Cal), at the
concentrations indicated. Results are means ± SEM. *P < 0.05 and **P < 0.01 vs. c; n = 3.
REN cells, as well as MeT-5A mesothelial cells, were cultured
in the presence of 2.5% serum and treated with calcitriol
and PEM, either individually or in combination for 72 h, the
appropriate time for PEM to be effective (22). PEM reduced
cell viability and proliferation at 10 and 50 nM in MSTO-
211H cells (Figures 3A,B) and at 50 and 100 nM in REN cells
(Figures 3C,D), with the maximum inhibitory effect observed
at the highest concentrations tested, as previously reported (22).
In MSTO-211H cells, the most responsive to PEM, 100 nM
calcitriol had no effect in combination with 10 nM PEM, while
it potentiated the inhibitory activity of 50 nM PEM on both cell
viability and survival (Figures 3A,B). The Combination Index
(CI), calculated for viability in MSTO-211H cells, was < 1
(0.944), indicating synergistic effect of 100 nM calcitriol and
50 nM PEM. In REN cells, the reduction induced by calcitriol was
significant only with 50 nM PEM for cell viability (Figure 3C),
likely because of the strong inhibitory effect of 100 nM PEM
alone, with a CI < 1 (0.426), indicating synergistic effect of
calcitriol and 50 nM PEM. Calcitriol also enhanced the effect
of PEM 50 and 100 nM on reduction of cell proliferation
(Figure 3D). Conversely, in line with the lack of effect observed
previously in mesothelial cells (Figures 2E,F), calcitriol did not
increase the cytotoxic activity of PEM in MeT-5A cells, at
any of the concentrations tested (Figures 3E,F). Overall, these
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FIGURE 3 | Inhibitory effects of calcitriol in combination with PEM. Cell viability
and proliferation assessed by MTT and BrdU, respectively, in MSTO-211H
(A,B) and REN (C,D) cell lines, and in MeT-5A mesothelial cells (E,F) treated
for 72 h in medium with 2.5% serum (c, control) and with either 100 nM
calcitriol (Cal) alone or with pemetrexed (PEM), at the concentrations indicated.
Results, expressed as percent of control, are means ± SEM. *P < 0.05, **P <
0.01, ***P < 0.001 vs. c; #P < 0.05, n = 4.
results indicate that calcitriol enhances the cytotoxic action of
chemotherapy drugs in MPM cells, while having no effect in
non-malignant cells.
Calcitriol Promotes Cell Cycle Arrest and
Inhibits the Expression of c-Myc and
Cyclins in MPM Cells Lines
To investigate the mechanisms involved in the inhibitory
activities of calcitriol, the cell cycle was analyzed in MPM
cells stained with propidium iodide. In both MSTO-211H and
REN cells, treatment with 100 nM calcitriol for 24 h caused
an increase in accumulation of cells in the quiescent G0/G1
phase, in concomitance with a decrease in the proportion of
cells in the active G2/M phase, while no effect was observed
at the lowest concentrations tested (Figures 4A,B). In keeping
with these findings, in MSTO-211H (Figures 4C–F) and REN
cells (Figures 4G–L) we observed a reduced expression in the
mRNA for c-Myc oncoprotein, and for cyclin A, cyclin D1 and
cyclin D2, all involved in cell cycle progression. By contrast,
apoptosis was not affected in any of the cell lines tested
(Supplementary Figures 2A–C). These findings suggest that the
antitumor effects of calcitriol in MPM cells involve cell cycle
arrest and inhibition of cell cycle progression.
Calcitriol Reduces Mitochondrial Function
in MPM Cell Lines
Mitochondria are essential regulators of cell viability, and cell
death is classically preceded by mitochondrial alterations in
the modulation of the complexes of respiratory chain and
oxidative phosphorylation (OXPHOS), as well as the loss of
mitochondrial membrane potential (1Ψm) (27). In addition,
previous studies have demonstrated the inhibitory effects of
vitamin D on mitochondrial respiratory activity in both normal
and cancer cells (16–18). Thus, mitochondrial function was
first evaluated by analyzing the alterations in expression of two
subunits of the respiratory chain complex IV, cytochrome c
oxidase (COX) subunits 2 and 4, of mitochondrial and nuclear
origin, respectively. Figures 5A,D shows that 24 h treatment
with calcitriol reduced the mRNA expression of COX2 at
50 nM in MSTO-211 and at 100 nM in REN cells. Similarly,
we observed inhibition in COX4 using 50 nM calcitriol in
MSTO-211H cells, and with both the concentrations tested in
REN cells (Figures 5B,E), whereas no changes were found for
both subunits in MeT-5A cells (Figures 5G,H). Calcitriol also
blunted1Ψm inMSTO-211H (Figure 5C) and REN (Figure 5F)
cells, while having no effect in MeT-5A cells (Figure 5I).
Overall, these results suggest inhibitory activities for calcitriol
in mitochondrial function in MPM cell lines, but not in non-
malignant mesothelial cells.
Calcitriol Decreases Cell Viability in Human
Primary MPM Cells
The effect of calcitriol was next assessed on viability of cells
isolated from pleural biopsies of patients with MPM. Calcitriol
was tested in a range of concentrations from 1 to 100 nM. In line
with previous findings (22), cell viability was reduced of ∼15–
20% in biphasic, epithelioid, and sarcomatoid cells cultured in
serum deprived conditions compared to the presence of serum
(data not shown). The addition of calcitriol, at 10 to 100 nM
in biphasic cells (Figure 6A), 50 and 100 nM in epithelioid
cells (Figure 6B) and 100 nM in sarcomatoid cells (Figure 6C)
caused a further decrease in cell viability, compared to untreated
cells, suggesting antitumor activities also in human primary
MPM cells.
DISCUSSION
This study shows that calcitriol, the active form of vitamin D,
reduces cell viability and growth of MPM cells; furthermore,
calcitriol potentiates the cytotoxic effect of the chemotherapy
drug PEM. The anticancer activities of calcitriol, also observed
in human primary MPM cells, involved inhibition of cell cycle
progression and dysregulation of mitochondrial function.
The biological activity of calcitriol is mainly regulated by
VDR, which modulates the expression of many target genes
(5, 28). Importantly, it has been shown that tumor progression
may be correlated with lower VDR levels in different types of
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FIGURE 4 | Role of calcitriol in cell cycle regulation in MPM cell lines. Representative images of cell distribution in G0/G1, S and G2/M phases analyzed by flow
cytometry using the Muse Cell Cycle kit in MSTO-211H (A) and REN cells (B) (Top panels), cultured in the presence of 2.5% serum, and either untreated (Control) or
treated with calcitriol (Cal) at the concentrations indicated. Results shown in graphs, are expressed as percentage of cells in each phase and are means ± SEM. **P <
0.01 and ***P < 0.001 vs. Control in each phase; n=3. Real-time PCR for c-Myc, cyclin A, cyclin D1, and cyclin D2 mRNA normalized to 18S rRNA in serum-starved
MSTO-211H cells (C–F) and REN cells (G–J) treated for 24 h with calcitriol (Cal) at the concentrations indicated. Results, expressed as fold change of control (c), are
means ± SEM of three independent experiments, each performed in duplicate. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. c.
cancer (5–9), and a positive association between expression of
VDR/calcitriol with improved prognosis was found in patients
with lung adenocarcinoma (29, 30). Furthermore, it has been
recently demonstrated that vitamin D deficiency exacerbates
pulmonary fibrosis in mice (31), whereas lung cancer cells
expressing VDR are more responsive to the antiproliferative
effect of calcitriol; in addition, high nuclear VDR expression has
been associated with increased survival in lung cancer patients
(29, 30, 32). Interestingly, studies suggested that an alteration in
VDR/vitamin D3 axis in mouse alveolar macrophages may lead
to pulmonary emphysema (33). In line with the above-mentioned
findings, future studies should be undertaken to assess the levels
of calcitriol and VDR in patients with MPM, which could have a
relevant prognostic value.
Calcitriol was previously found to increase VDR expression in
different cancer cells, as well as in bronchial epithelial cells and
peritoneal mesothelial cells, along with inhibition of epithelial
to mesenchymal transition (5, 8, 34). However, the presence
of VDR in MPM cell lines has yet to be examined. Here, we
show that VDR expression is much higher in MSTO-211H
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FIGURE 5 | Effect of calcitriol on mitochondrial metabolism in MPM cells. Real-time PCR for COX2 and COX4 mRNA expression in MSTO-211H (A,B), REN (D,E),
and MeT-5A cells (G,H), serum starved for 12 h then treated for 24 h with calcitriol (Cal) at the concentrations indicated. Results, normalized to18S rRNA are
expressed as fold change of vehicle are means ± SEM. *P < 0.05, **P < 0.01 and ***P< 0.001 vs. c; ns, not significant; n = 3. Mitochondrial membrane potential
(1Ψm) assessed by flow cytometry analysis of JC-1 in MSTO-211H (C), REN (F) and MeT-5A cells (I) treated for 24 h in medium with 1% serum (c, control medium),
and either with or without calcitriol (Cal) at the concentrations indicated. Red to green (FL-2/FL-1) ratio was calculated in each experimental condition and expressed
as percent of untreated cells. Results are means ± SEM. *P < 0.05, *P < 0.01 vs. c; n = 3.
FIGURE 6 | Inhibitory effects of calcitriol in primary MPM cells. Cell viability (MTT assay) in biphasic (A), epithelioid (B), and sarcomatoid (C) primary MPM cells
cultured in serum-deprived medium (c, control) for 12 h, then treated for 24 h with calcitriol (Cal), at the concentrations indicated. Results, expressed as percent of
control, are means ± SEM. *P < 0.05 vs. c; n = 3.
and REN than in MeT-5A cells, and is further increased by
treatment with calcitriol, at both the cytoplasmic and nuclear
level. VDR can be up-regulated by vitamin D at both the
transcriptional and post-translational levels, the latter through a
ligand-dependent stabilization (28). Possibly depending on both
genomic (transcriptional) (35) or non-genomic (stabilization)
(36) mechanisms, equally active after 24 h of treatment, we
found that in MPM cell lines calcitriol increased VDR levels
and promoted its nuclear translocation. Instead, basal VDR
levels were modest in MeT-5A cells and remained unchanged
after treatment with calcitriol, which would explain the lack
of inhibitory activity in non-malignant cells, in line with
previous findings (34). The induction of the catabolic enzyme
24-hydroxylase may justify the resistance of MeT-5A cells to
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vitamin D action, and possible differences among cell types,
already described in other models (19), could be discovered also
in mesothelial cells in future studies.
Another crucial difference among the cell lines tested could be
due to the epigenetic remodeling affecting the vitaminD response
elements (VDREs) present in many genes. In fact, VDREs
mediate the genomic activity of vitamin D/VDR and control
the transcription of VDR itself. The accessibility of VDREs is
regulated by epigenetic mechanisms and modulated depending
on the cell type and differentiation status (37). Alterations of
VDR cistrome (the ensemble of VDREs open to VDR docking)
could be responsible for different genomic responses to calcitriol
in our experimental model; this is an interesting aspect that
warrants further investigation.
The antitumor role of calcitriol and vitamin D derivatives
in different types of cancer was demonstrated in several in
vitro and in vivo studies, including lung cancer, suggesting that
vitamin D may be a promising agent, in combination with
anticancer therapies (5, 7–9, 38). Importantly, inflammation
is one of the main hallmarks of cancer (39) and different
studies have demonstrated the ability of vitamin D to modulate
the innate and adaptive immune responses and to exert
antinflammatory effects in tumorigenesis, by interfering with
the tumor microenvironment through the regulation of key
inflammatory pathways (5, 40, 41). Here, we report for the first
time that calcitriol inhibits cell viability and growth of human
epithelioid and biphasicMPM cell lines and blunts the viability of
all primary MPM cell subtypes, suggesting anticancer properties
in both the most and least aggressive phenotypes, while having
no effect in mesothelial cells. These activities were observed at
concentrations consistent with those previously reported in other
cancer cell types (30, 42, 43). Interestingly, the ability of calcitriol
to reduce viability inMPMcell lines wasmaintained even inmore
physiological conditions, i.e., in cells cultured with serum and
after longer term treatment.
Robinson et al. previously showed that diet supplementation
with cholecalciferol in a transgenic mouse model of asbestos-
induced mesothelioma (MexTAg) had no effect on the incidence
or severity of peritoneal mesothelioma (20). However, this model
is different from the traditional human cancer xenograft (5, 8, 21);
furthermore, mesothelioma cells from MexTAg mice showed
increased expression of genes involved in the control of cell
cycle, proliferation pathways or DNA replication, compared
with those obtained from MPM of wild-type mice (44), likely
because of the high expression of SV40 large T Antigen (TAg) in
the mesothelial compartment, suggesting increased resistance to
anticancer drugs. In addition, the direct action of cholecalciferol
in mesothelioma cells of these mice was not examined (20).
Although the antitumor effects of calcitriol in preclinical
models has been largely demonstrated, the single vitamin
D analogs have limited efficacy in cancer therapy; thus,
combination therapies with calcitriol and compounds such as
glucocorticoids, cytotoxic drugs, inhibitors or retinoids have been
widely investigated (9). Herein, we show that, in addition to
the effect per se, calcitriol also acted in a synergistic manner
with the antifolate compound PEM, which, in association with
cisplatin, is currently the standard first-line treatment for patients
with advanced MPM (4). To the best of our knowledge, this is
the first evidence on the effective combination of calcitriol and
PEM in cancer cells, despite vitamin D derivatives previously
showed the ability to potentiate in vitro and in vivo the antitumor
effects of platinum analogs like carboplatin and cisplatin (5,
9, 45). Therefore, although not suitable as a single use against
cancer, vitamin D derivatives might be considered as adjuvants
in combination therapy with cytotoxic compounds, as already
described for other types of cancers (9, 11). On the other hand,
vitamin E isoforms with anticancer properties were found to
attenuate in vitro chemoresistance to cisplatin and to inhibit the
growth of human MPM cell lines, without altering the growth of
non-malignant mesothelial cells (46, 47).
In the present study, we did not observe an increase in
apoptosis in MPM cells treated with calcitriol, in agreement with
previous studies showing that calcitriol inhibits cell proliferation
in human lung cancer and adrenocortical carcinoma cell lines,
with no effect on apoptosis (30, 48). Interestingly, we found
that calcitriol increases the proportion of cells in the quiescent
phase of cell cycle (G0/G1), while reducing those in G2/M,
indicating that the antiproliferative effects are associated with
cell cycle arrest, in line with results in other cancer cells (8, 38).
Furthermore, calcitriol inhibited the expression of c-Myc and
cyclin A, D1 and D2, all involved in the control of cell cycle (22,
24, 30, 49), in keeping with its ability to suppress the expression
of c-Myc-regulated genes and to promote cell cycle arrest and
inhibition of cyclins in both normal and cancer cells (30, 50, 51).
c-Myc is a protooncogene frequently deregulated inmany human
cancers, whose inhibition induces apoptosis and sensitizes MPM
cells to drug-induced cytotoxicity (52); moreover, we recently
showed that c-Myc is implicated in the antitumor effects of
growth-hormone releasing hormone (GHRH) antagonists in
MPM cell lines (22).
In addition to the previously known nuclear effects of
calcitriol in the control of cell proliferation, a novel finding of
this study is the demonstration of the mitochondrial activity of
VDR in mesothelioma. We and others previously demonstrated
the ability of vitamin D to reduce the mitochondrial respiratory
activity in both normal and cancer cells (16–18). Herein, calcitriol
decreased the mitochondrial function, measured as inhibited
transcription of respiratory complexes COX2 and COX4, and
as reduced membrane potential, which is proportional to the
respiratory activity. Although the reduction of COX2 and COX4
was small, our result is in line with the fact that strong inhibition
would lead to mitochondrial dysfunction and apoptosis (53), and
we did not observed apoptosis after treatment of MPM cells
with calcitriol, suggesting that the effects on COX expression are
mostly metabolic. The consequences of a reduced mitochondrial
activity can be different, depending on the sensitivity to the
differentiating nuclear activity of vitamin D and according to
the genetic and epigenetic asset of the cells, as demonstrated in
our studies in human keratinocytes and cancer cell lines (17–
19). When the cells are resistant to the nuclear differentiating
effects, the reduced mitochondrial activity reroutes the metabolic
intermediates toward the biosynthetic pathways supporting
proliferation (17), whereas when vitamin D exerts its nuclear
control, the spared intermediates are employed in the specific
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metabolism of the tissue (19). In humanMPM cells we found that
calcitriol exerts nuclear antiproliferative effects and potentiates
the antiproliferative activity of PEM in a synergistic manner.
In addition, the inhibition of mitochondrial activity must
reduce the energy supply of mesothelioma, thus increasing the
cytotoxicity of the drug, possibly by a reduced ATP-dependent
drug extrusion. Similarly, we recently reported the reduction
of 1Ψm in response to the antiproliferative effects of GHRH
antagonists in MPM cell lines (21). Differently from other
studies that demonstrated an association between cell growth
arrest and apoptosis, due to the inhibition of OXPHOS complex
subunits and 1Ψm in MPM treated with mitochondria-targeted
molecules (43), we did not find evidences for a proapoptotic effect
of mitochondrial inhibition.
Overall, the results of this study demonstrate the inhibitory
effect of calcitriol on viability and growth of MPM cells,
either alone or in combination with PEM, through mechanisms
involving cell cycle arrest and inhibition of the mitochondrial
activity, suggesting that vitamin D derivatives, in association
with chemotherapy drugs, could have potential in the treatment
of MPM.
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